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Abstract
Objective: The primary goal of this study was to identify brain atrophy from
structural MRI (magnetic resonance imaging) and cerebral blood flow (CBF)
patterns from arterial spin labeling perfusion MRI that are best predictors of
the Ab-burden, measured as composite 18F-AV45-PET (positron emission
tomography) uptake, in individuals with early mild cognitive impairment
(MCI). Furthermore, another objective was to assess the relative importance of
imaging modalities in classification of Ab+/Ab early MCI. Methods: Sixty-
seven Alzheimer’s Disease Neuroimaging Initiative (ADNI)-GO/2 participants
with early MCI were included. Voxel-wise anatomical shape variation measures
were computed by estimating the initial diffeomorphic mapping momenta from
an unbiased control template. CBF measures normalized to average motor cor-
tex CBF were mapped onto the template space. Using partial least squares
regression, we identified the structural and CBF signatures of Ab after account-
ing for normal cofounding effects of age, gender, and education. Results: 18F-
AV45-positive early MCIs could be identified with 83% classification accuracy,
87% positive predictive value, and 84% negative predictive value by multidisci-
plinary classifiers combining demographics data, ApoE e4-genotype, and a mul-
timodal MRI-based Ab score. Interpretation: Multimodal MRI can be used to
predict the amyloid status of early-MCI individuals. MRI is a very attractive
candidate for the identification of inexpensive and noninvasive surrogate bio-
markers of Ab deposition. Our approach is expected to have value for the iden-
tification of individuals likely to be Ab+ in circumstances where cost or
logistical problems prevent Ab detection using cerebrospinal fluid analysis or
Ab-PET. This can also be used in clinical settings and clinical trials, aiding sub-
ject recruitment and evaluation of treatment efficacy. Imputation of the Ab-
positivity status could also complement Ab-PET by identifying individuals who
would benefit the most from this assessment.
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Introduction
Amyloid-b (Ab) peptides form cortical plaques, a major fea-
ture of Alzheimer’s disease (AD) neuropathology.1 Approx-
imately 30–50% of brains from the individuals with latent
or prodromal AD over age 60 harbor Ab-pathology in a
similar pattern to that seen in AD.1 In the Alzheimer’s Dis-
ease Neuroimaging Initiative (ADNI) study 46% of patients
with early mild cognitive impairment (MCI) were Ab-posi-
tive, suggesting that these subjects had prodromal AD, while
54% did not have significant brain Ab accumulation. These
findings, together with many other reports2,3 indicate that
clinical assessment alone has limited utility to detect early
AD pathology in many individuals. Whether these individu-
als will later develop cognitive decline and dementia due to
AD remains unknown; however, evidence of brain Ab accu-
mulation increases the risk for progression from clinical
dementia rating (CDR) 0 to CDR 0.5 status by fivefold, and
conversion from MCI to AD by threefold.4 Therefore,
earlier, more accurate, biomarker-based detection of
AD-related Ab pathology is crucial and could potentially
offer a greater opportunity for initiation of disease-modifying
therapies prior to the advanced stages of AD.
Brain Ab deposition can be detected by molecular
imaging techniques such as positron emission tomogra-
phy (PET) using an Ab-specific radioligand, or through
measurement of cerebrospinal fluid (CSF) Ab1-42 concen-
tration. Both of these measures show high correlations
with postmortem measures of fibrillar Ab.5–7 Lumbar
puncture, required for CSF sample collection, carries a
4% risk of a clinically significant adverse event (e.g.,
post-lumbar puncture headache, moderate atypical head-
ache, moderate low back pain, vasovagal episode)8 and is,
therefore, unattractive as a population screening tool, par-
ticularly in early-stage individuals. Neuroimaging has the
advantage of being less invasive and PET tracers have
been changing the field by enabling in vivo Ab plaque
detection. However, PET is relatively expensive with lim-
ited availability and contributes to the patient’s overall
long-term cumulative radiation exposure, which is associ-
ated with an increased risk of cancer.9
There is an emerging literature investigating Ab-related
brain changes using structural MRI (magnetic resonance
imaging) describing an association between Ab burden
(e.g., low CSF Ab1-42 or high Ab-PET binding) and atro-
phy, especially of the parietal and posterior cingulate
regions, extending into the precuneus and medial tempo-
ral regions including hippocampus, amygdala, and en-
torhinal cortex.10–16 Although not as substantial as the
structural studies, arterial spin labeling (ASL) MRI studies
also show Ab-related cerebral blood flow (CBF) changes
including reduced CBF in the cingulate, supramarginal
gyrus, thalamus, and midbrain, as well as increased CBF
in the medial and inferior frontal, precuneus, and inferior
parietal regions.17–19 These findings suggest that Ab accu-
mulation is associated with structural and CBF changes,
both of which can be detected with MRI.
The primary goal of this study was to develop a method to
predict which subjects with early MCI have Ab deposition,
by using MRI-detected changes of brain structure and CBF.
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The study cohort consisted of 67 individuals with early MCI
between the ages of 60 and 85 years and 33 Ab-negative
cognitively normal (CN) elderly individuals, to model the
normal confounding effects of age, gender, and education,
all recruited by ADNI. Global Ab burden, determined by Ab
PET using 18F-AV45 radioligand (florbetapir), served as
outcome variable in primary hypotheses testing. The predic-
tors included high-dimensional measures of anatomical
shape variations from structural MRI and regional CBF from
ASL-MRI, as well as demographics and Apolipoprotein E
(ApoE) genotype. Our central hypothesis was that even the
earliest Ab-related structural and CBF changes could be
detected in vivo using clinically viable metrics to construct a
robust mathematical Ab prediction model. This will help to
develop clinically viable early surrogate biomarkers of AD
pathology in prodromal individuals. This will have a broad
use in early diagnosis, facilitating initiation of prevention
strategies in those at risk, and boost the power of anti-Ab
immunotherapy trials by selecting those at greatest risk of
AD. As a secondary goal, we assessed the relative importance
of imaging modalities in classification of 18F-AV45-positive
versus 18F-AV45-negative early-MCI individuals.
Methods
Participants
Data used in the preparation of this article were obtained
from the ADNI database (adni.loni.ucla.edu). The ADNI
was launched in 2003 by the National Institute on Aging,
the National Institute of Biomedical Imaging and Bio-
engineering, the Food and Drug Administration, private
pharmaceutical companies and non-profit organizations,
as a $60 million, 5-year public private partnership. The
primary goal of ADNI has been to test whether serial
MRI, PET, other biological markers, and clinical and neu-
ropsychological assessment can be combined to measure
the progression of MCI and early AD. Determination of
sensitive and specific markers of very early AD progres-
sion is intended to aid researchers and clinicians to
develop new treatments and monitor their effectiveness,
as well as to lessen the time and cost of clinical trials.
The Principal Investigator of this initiative is Michael
W. Weiner, MD, VA Medical Center and University of
California – San Francisco. ADNI is the result of efforts
of many co investigators from a broad range of academic
institutions and private corporations, and subjects have
been recruited from over 50 sites across the U.S. and
Canada. The initial goal of ADNI was to recruit 800 sub-
jects but ADNI has been followed by ADNI-GO and
ADNI-2. To date, these three protocols have recruited
over 1500 adults, ages 55–90, to participate in the
research, consisting of CN older individuals, people with
early or late MCI, and people with early AD. The
follow-up duration of each group is specified in the pro-
tocols for ADNI-1, ADNI-2 and ADNI-GO. Subjects orig-
inally recruited for ADNI-1 and ADNI-GO had the
option to be followed in ADNI-2. For up-to-date infor-
mation, see www.adni-info.org.
Data for this study were limited to baseline scans from
ADNI-GO/2 participants in the ASL-MRI substudy as of
June 2013. This cohort included 33 CN elderly individuals
(CN) and 67 early-MCI subjects, representative of the
broader ADNI-GO/2 CN and early-MCI participants (cf
Tables S1–S2). Full inclusion and exclusion criteria for
ADNI are described at www.adni-info.org. In brief, CN
subjects had mini-mental state examination (MMSE) scores
between 24 and 30, a CDR of 0, no evidence of depression,
and no memory complaints. Individuals with MCI were
classified essentially in the manner described by Petersen,20
but were then further divided into an “early” and “late”
group based on performance on the Wechsler Memory
Scale–Revised Logical Memory II (WMS-LM). The early-
MCI group was defined based on scores between the cutoff
of CN and that of the late-MCI group.
Baseline MRIs of CN subjects were used to model the
normal confounding effects of age, gender, and education
on anatomical shape variation and CBF measures. Previ-
ous studies reported that the cumulative and regional Ab
burden in CN subjects correlate with regional brain atro-
phy and CBF changes.10,17,21 Furthermore, CN subjects at
genetic risk for AD by virtue of the ApoE e4-allele dem-
onstrated regional brain atrophy and CBF differences rela-
tive to e4-noncarriers.22,23 Therefore, we included only
the ApoE e4-noncarrier CN subjects who were identified
as Ab-negative using 18F-AV45-PET. Furthermore, ApoE
e2-allele carrier CN and early-MCI subjects were excluded
due to sample size limitations. Study group demographics
are summarized in Table 1.
Table 1. Demographic information of subject groups.
Cognitively
healthy
elderly Early MCI P-value
Number of subjects 33 67 –
Age 72.80  6.04 69.76  6.61 0.025
Gender (F/M) 19/14 22/45 0.040
Education 16.70  2.30 16.57  2.66 0.788
ApoE e4 genotype
(e3/e3, e3/e4, e4/e4)
33, 0, 0 41, 23, 3 <0.0001
MMSE 29.24  1.06 28.79  1.21 0.061
CDR-SB 0.02  0.09 1.23  0.81 <0.0001
ADAS-Cog 6.42  3.56 7.65  3.35 0.094
18F-AV45-PET SUVR 1.00  0.05 1.16  0.18 <0.0001
18F-AV45-positive (%) 0% 50% <0.0001
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18F-AV45-PET
18F-AV45-PET scans were acquired 50–70 min after injec-
tion of 10 mCi of tracer. Images underwent a rigorous
quality control protocol and were processed to produce
final images with standard orientation, voxel size, and
8 mm resolution by the ADNI-PET Core.24 Briefly, scans
were analyzed in native space using the subjects’ structural
MRIs acquired close to the time of the 18F-AV45-PET
scans. Structural MRIs were segmented into cortical regions
using FreeSurfer version 4.5.0 (surfer.nmr.mgh.har-
vard.edu/). These cortical regions of interest (ROIs) were
used to extract 18F-AV45-PET uptake from gray matter
(GM) in lateral and medial frontal, anterior, and posterior
cingulate, lateral parietal, and lateral temporal cortex. Val-
ues were normalized to florbetapir-PET uptake in the
whole cerebellum. The averaged cortical uptake in this
composite ROI was used as the index of florbetapir-PET
uptake, that is, standard uptake value ratio (SUVR), in each
subject. Furthermore, subjects were characterized as 18F-
AV45-positive or 18F-AV45-negative based on a threshold
value of 1.11 for the 18F-AV45-SUVR.25
Multimodality MRI acquisition
Both high-resolution structural MRI and ASL-MRI were
acquired at ADNI-GO/2 sites equipped with 3T Siemens
MRI scanners. Two structural MRIs were acquired using
a 3D magnetization prepared rapid gradient echo
(MPRAGE) T1-weighted sequence with the following
parameters: TR/TE/TI = 2300/2.98/900 msec, 176 sagittal
slices, within plane field-of-view (FOV) = 256 9
240 mm2, voxel size = 1.1 9 1.1 9 1.2 mm3, flip angle =
9°, bandwidth = 240 Hz/pix. A designated center selected
the MPRAGE image with higher quality and corrected for
system-specific image artifacts such as geometry distor-
tion, B1 nonuniformity, and intensity inhomogeneities.26
ASL-MRIs were acquired using the Siemens product
proximal inversion with control for off-resonance effects
sequence, which is a pulsed ASL sequence using the
Q2TIPs technique for defining the spin bolus. The acqui-
sition parameters were: TR/TE = 3400/12 msec, TI1/
TI2 = 700/1900 msec, FOV = 256 mm, 24 sequential 4-
mm thick slices with a 25% gap between the adjacent
slices, partial Fourier factor = 6/8, bandwidth = 2368 Hz/
pix, and imaging matrix = 64 9 64.
Anatomical shape variations
Skull, scalp, and extracranial tissue were removed from
each structural MRI using the automated Brain Surface
Extraction software,27 followed by manual refinement if
required. To avoid bias toward a particular subject’s
geometry in analysis of anatomical shape variations, we
used the data from CNs to create a study-specific
unbiased large deformation brain image template (ULD-
template) by applying a framework of large deformation
diffeomorphic metric mapping (LDDMM) as described in
full elsewhere.28 ULD-template generation incorporated
an unbiased approach where all brain images were first
simultaneously affine transformed to adjust for global
variations in brain positioning and scale, and then simul-
taneously deformed. Structural MRI of each early-MCI
subject was first affine aligned and then nonlinearly
warped to this ULD-template using the LDDMM frame-
work. The LDDMM was modeled as an evolution in time,
with an associated smooth velocity vector field controlling
this evolution. A scalar initial momentum map parame-
terized the entire geodesic with which the optimal trajec-
tory emanated from the ULD-template to reach a subject
brain image on a Riemannian manifold of diffeomor-
phism.28 These momentum maps uniquely encoded the
anatomical shape variations of individual brains relative
to the ULD-template.
Cerebral blood flow
ASL-MRI processing was performed to obtain partial vol-
ume-corrected maps of CBF, as previously described.29–33
Individual ASL-MRI frames were coregistered using rigid
body registration to reduce movement artifacts. Geomet-
ric distortion correction on ASL-MRI with respect to the
affine-aligned T2-weighted MRI was estimated using a
variation image-based approach for correction of suscep-
tibility artifacts.34 Motion and distortion corrected images
were normalized to the ASL reference scan signal (the
first volume of the ASL acquisitions), without background
suppression, to account for B1-field variations. The
dynamic ASL data were fitted voxel-by-voxel to a dual
compartment perfusion model, which takes into account
variable transit times, bolus durations, distributed con-
centrations of capillary water and restricted brain-blood
barrier permeability.35 This model yielded a parametric
map for CBF. The ASL reference scan signal without
background suppression was rigidly coregistered, first to
T2-weighted and then to MPRAGE-MRI, to map the
parametric CBF measures to the structural-imaging space,
where anatomical tissue compartments were defined by
an adaptive fuzzy c-means algorithm.36 Variations of CBF
due to partially volumed GM voxels were accounted for
by voxel-wise analysis of covariance, in which the tissue
compartment estimates were entered as regressors. To
account for global variations in CBF between and within
individuals, CBF maps were intensity normalized by aver-
age CBF in the motor cortex, which is spared in AD. The
resultant CBF maps were resampled to the ULD-template
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image space via the corresponding LDDMM vector fields,
estimated for the corresponding structural MRI.
Covariates
We used a general linear model based detrending method
to control for any normal confounding effects of age,
gender, and education, based on 18F-AV45-negative and
ApoE e3/e3 CN subjects. Adjusted imaging measures of
anatomical shape variation and CBF were used for further
data analyses.
Neuroimaging correlates of Ab burden
MR imaging provides high-throughput data for discovery
of surrogate biomarkers for Ab pathology, but the high-
dimensional data based on a relatively small number of
participants inherently comes with significant codepen-
dencies and contain a large number of association pat-
terns, most of which are erroneous or redundant. Our
goal was to identify which of these are significant associa-
tions, with high predictive power. Partial least squares
(PLS) regression37 has the ability to handle high-dimen-
sion, low sample size, multicollinear data, while searching
for modes that explain the maximum covariance between
the explanatory and response spaces. We used PLS regres-
sion with the neuroimaging measures (i.e., anatomical
shape variation and CBF) from each and every imaging
voxel as predictors to assess the patterns of neuroimag-
ing-Ab associations. In joint analysis of anatomical shape
variation and CBF measures, we first normalized each
imaging data to have unit variance and then combined
the data to form a product space defined by their convex
combination with a relative weighting coefficient of
0 ≤ k ≤ 1, that is, k = 0 for pure CBF correlates of Ab
and k = 1 for pure anatomical shape variation correlates
of Ab. For a given k, the statistical significance of the
neuroimaging-Ab associations inferred by PLS regression
was assessed using the projected data and non-parametric
permutation testing. Furthermore, a k-dependent neuroi-
maging-based Ab score was calculated by projecting each
individual’s neuroimaging data onto the latent variable
(LV) inferred by the corresponding PLS regression.
Classification of Ab+ early-MCI individuals
To create a mathematical function that best combines the
neuroimaging-based Ab score, demographics (i.e., age, gen-
der, and education), and ApoE genotype to give a binary
prediction of Ab+ in early-MCI individuals, we based our
classification model to a logistic regression with least abso-
lute shrinkage and selection operator (LASSO). The neuroi-
maging-based Ab score, age, gender, education, and ApoE
genotype were the independent predictor variables. The
dependent outcome variable was the Ab+/ dichotomiza-
tion, based on 18F-AV45-PET scans and established
standardized 18F-AV45 uptake threshold.25 For 10-fold
cross-validation of the classifier performance, the data were
divided into 10 subsets of cases that had similar size and
Ab+/ distributions. Each subset was left out once, while
the other nine was applied to construct a neuroimaging-
based Ab score and a classifier subsequently validated for
the unseen cases in the left-out subset. Classifier perfor-
mance assessment was based on classification accuracy
(CA), positive predictive value (PPV), and negative predic-
tive value (NPV). Performance of the best performing clas-
sifier with nonimaging factors was referenced to test the
added value of neuroimaging in classification of Ab+/Ab
early MCI. Finally, to assess the relative importance of
structural and ASL imaging data, we constructed the neu-
roimaging-based Ab score and classifier for various k values
in the range (0, 1) with 0.05 increments.
Results
Demographic characteristics
Demographic characteristics of the subjects are summa-
rized in Table 1. On average, early MCIs were signifi-
cantly younger than CNs (t = 2.29, P = 0.02), although
still in the same age range. Early-MCI group had dispro-
portionately higher male subjects compared with CN
group (v2 = 4.23, P = 0.04). Consistent with the ADNI
recruitment criteria and our study design, early-MCI and
CN groups differed in the clinical measure of CDR-SB,
18F-AV45-SUVR (two-sample t-tests; P < 0.0001), 18F-
AV45-positive/negative ratio, and ApoE e4-allele fre-
quency (chi-squared contingency table test; P < 0.0001).
Neuroimaging signatures of brain
amyloidosis
Figure 1A shows the spatial signature of the LV inferred
by PLS regression for k = 1, that is, anatomical shape
variation signature of brain Ab-burden in early MCI.
Dark red/blue and white colors indicate greater contribu-
tion of the local anatomical shape variations to the LV,
therefore to the structural-Ab association. Increased
18F-AV45-SUVR was associated with anatomical shape
variations largely in the frontoparietal cortical regions
including inferior parietal, precuneus, supramarginal,
postcentral, middle frontal, and to a lesser extent in the
temporal lobe regions including superior temporal, en-
torhinal, hippocampus, and subcortical regions including
amygdala, nucleus accumbens, and caudate (r = 0.93;
P < 0.0001).
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The spatial signature of the LV inferred by PLS regres-
sion for k = 0, that is, CBF signature of brain Ab-burden
in early MCI, is shown in Figure 1B. Hypoperfusion
regions are colored in shades of blue and hyperperfusion
regions are colored in shades of red. Increased 18F-AV45-
SUVR was associated with hypoperfusion primarily in the
medial temporal regions, including hippocampus, entorh-
inal, parahippocampus, fusiform, temporal pole, amyg-
dala, as well as with hyperperfusion largely localized in
the inferior parietal lobule but also including inferior
frontal, postcentral, and precuneus regions (r = 0.77;
P < 0.0001).
Ab+ predictive power of the neuroimaging-
based Ab scores alone and in combination
with other nonimaging variables
Estimated performances of the LASSO penalized logistic
regression classifiers with nonimaging variables (i.e., age,
gender, years of education, and ApoE-e4 genotype) alone
and jointly with neuroimaging-based Ab scores are
reported in Table 2. All classifiers considered in this study
performed significantly better than chance (P < 0.01).
ApoE e4-genotype jointly with demographics data classi-
fied 18F-AV45-positive early MCIs with a 69% CA, 73%
PPV, and 70% NPV. Both pure structural- and pure ASL-
MRI-based Ab scores outperformed the ApoE e4-geno-
type (P < 0.01) and reached higher CAs (79% and 75%,
respectively), higher PPVs (81% and 76%, respectively),
and higher NPVs (80% and 78%, respectively). A multi-
disciplinary classifier combining demographics, ApoE
e4-genotype, and neuroimaging-based Ab scores reached
80–83% CA, 82–85% PPV, and 82–83% NPV in identify-
ing 18F-AV45-positive early MCIs.
Relative importance of imaging modalities
in identifying 18F-AV45-positive early MCIs
Performance of the multidisciplinary classifier as a func-
tion of k, relative weighting coefficient for structural MRI
and ASL-MRI in the construction of the neuroimaging-
Figure 1. Neuroimaging signatures of brain amyloidosis in early MCI.
Table 2. Estimated performances of the LASSO penalized logistic
regression classifiers in predicting 18F-AV45-positivity in early MCI.
Predictors CA PPV NPV
Demographics (age,
gender, years of
education)
0.65  0.03 0.67  0.03 0.66  0.04
Demographics and ApoE
e4 genotype
0.69  0.08 0.73  0.09 0.70  0.10
Demographics and sMRI-
based Ab burden score
0.79  0.05 0.81  0.06 0.80  0.07
Demographics and ASL-
based Ab burden score
0.75  0.11 0.76  0.12 0.78  0.10
Demographics and ApoE
e4 genotype and sMRI-
based Ab burden score
0.83  0.03 0.85  0.02 0.83  0.04
Demographics and ApoE
e4 genotype and ASL-
based Ab burden score
0.80  0.06 0.82  0.06 0.82  0.02
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based Ab score, is plotted in Figure 2. Maximal CA
(≥83%), PPV (≥87%), and NPV (≥84%) were achieved
with 0.25 ≤ k < 0.5. Added value of multimodality-MRI
over unimodality MRI was significant (P < 0.01) only in
terms of PPV of the final classifier.
Discussion
The major findings of this study were (1) 18F-AV45-posi-
tive early-MCI subjects could be identified with a
CA ≥ 83%, PPV ≥ 87%, and NPV ≥ 84% by a multidis-
ciplinary classifier combining demographics data, ApoE
e4-genotype, and multimodality MRI-based Ab score; (2)
this maximal 18F-AV45-positivity classifier performance
was achieved with a relative weighting coefficient of
0.25 ≤ k < 0.5 for structural MRI and ASL-MRI, imply-
ing the dominance of CBF changes in predicting
18F-AV45-positivity in early MCI; and (3) greater cortical
18F-AV45-SUVR in early MCI was associated with pat-
terns of anatomical shape variations predominantly in the
fronto-parietal regions, patterns of hypoperfusion in med-
ial temporal cortices, and patterns of hyperperfusion local-
ized to inferior parietal lobule. Taken together these results
demonstrate that structural MRI and ASL-MRI can be used
to predict the Ab status of individuals with early MCI.
We previously pursued the use of structural MRI in
predicting widespread brain Ab deposition in individuals
with MCI.38 Although the overall objective of this study
is similar to our previous work, the contribution of this
study is twofold: First, the primary goal of this study was
to develop a method to predict which subjects with early
MCI have brain Ab deposition, by using MRI-detected
changes of brain structure and CBF. Expected smaller
effect size estimates for both functional and structural
brain changes make it challenging to adequately power to
construct a robust mathematical Ab prediction model for
early-MCI. Second, to the best of our knowledge, this is
the first neuroimaging study showing the value of struc-
tural MRI and ASL-MRI as predictors of the likelihood of
significant Ab accumulation, both independently and
jointly. According to our findings, the added value of
multimodal MRI is incremental yet significant especially
in terms of the PPV of the proposed early-MCI Ab-posi-
tivity predictor. We demonstrated that with multimodali-
ty MRI, basic demographics, and ApoE genotype data, we
could achieve an 83% CA with an 87% PPV and an 85%
NPV in identifying 18F-AV45-positive early-MCI. This
multimodality/multidisciplinary classification model out-
performed other classifiers considered in this study using
either nonimaging factors or unimodality neuroimaging
data. Such an Ab-positivity classifier would greatly
improve the efficiency of clinical trials targeting the early
disease stages by reducing the number of subjects needed
to be screened with Ab-PET scans or lumbar punctures.
Specifically, based on the 87% PPV, to enroll 100
18F-AV45-positive early-MCI participants, screening on
structural and CBF variations in addition to age, gender,
education, and ApoE genotype can reduce the number
needed to screen by 47%, resulting in screening of only
15 additional participants than the targeted number.
According to our analyses, the added value of multimo-
dality neuroimaging data to age, gender, education, and
ApoE genotype information is a 14% increase in the CA,
as well as in PPV and NPV of the final Ab-positivity pre-
diction model. The 14% difference in PPV and NPV met-
rics translates to a 20% difference in both the number of
subjects needed to screen for recruitment and the number
of subjects needed to screen with Ab-PET scans.
There is an emerging literature investigating Ab-related
brain changes using structural MRI describing an associa-
tion between Ab burden (e.g., low CSF Ab1-42 or high
Ab-PET binding) and atrophy, especially of the parietal
and posterior cingulate regions, extending into the
precuneus and medial temporal regions including
Figure 2. Performance of the multidisciplinary classifier as a function of k, relative weighting coefficient for structural MRI and ASL-MRI in the
construction of the neuroimaging-based Ab score.
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hippocampus, amygdala, and entorhinal cortex. This pari-
etotemporal dominant pattern of Ab-atrophy association
is even evident at mild stages of cognitive deficits.10–16,39–41
A surprising finding of this study showed that in early
MCI, Ab-related anatomical shape variations were wide-
spread, and showed a superior–inferior gradient with ana-
tomical shape variations in the parietal and frontal
regions exhibiting greater associations with Ab-burden
than temporal and occipital regions. This early-MCI ana-
tomical shape variation signature of brain Ab is mainly
in agreement with the Ab-accumulation patterns reported
for elderly individuals,2,42 affecting predominantly parietal
and frontal brain regions more than temporal and occipi-
tal brain regions with a superior–inferior gradient.2,42
This suggests a localized effect of Ab pathology on brain
structure in early-MCI individuals. In contrast to the
structural-Ab association pattern, the early-MCI CBF sig-
nature of brain Ab involved several AD-related neurode-
generation brain regions, in agreement with many
previous reports of altered tempero-parietal CBF in AD
continuum.30,43–52 Our finding of spatial pattern CBF-Ab
association being distributed rather than being localized
to Ab accumulation sites suggests a greater involvement
of a memory network including hippocampal complex in
Ab-related CBF changes in early MCI. Future studies
examining the temporal dynamics of Ab accumulation,
atrophy, and CBF changes could further our understand-
ing of pathophysiological processes in early disease stages.
The strength of this study is the approach we used to
predict the likelihood of significant Ab accumulation in
early MCI. We applied a combination of state-of-the-art,
yet clinically feasible, 3T neuroimaging techniques for
quantification of voxel-based brain anatomical and CBF
changes, and modern multivariate statistical analysis
methods that allow simultaneous testing of variations
across modalities and brain regions to maximally exploit
information and to relate these high-dimensional brain
alterations to measure of global brain Ab accumulation.
Although neuroimaging research has made major progress
in linking Ab and AD-related neurodegeneration, the
majority of these studies have analyzed each neuroimag-
ing modality in isolation, ignoring relationships between
the measures that might carry important predictive infor-
mation for Ab-positivity. Moreover, aside from a small
number of studies,38,40,53 most neuroimaging studies and
especially those using structural MRI, evaluate variations
in the brain region-by-region, ignoring the network con-
nectivity changes that could reflect the pathological foot-
print of Ab accumulation.
A potential limitation of this study is that findings
from the ADNI may not precisely generalize to general
population. In particular, ADNI population represents a
clinical trial population and not an epidemiologically
selected real life population. Other study limitations
include the inherent limitations of the ASL technique,
namely that it has low signal-to-noise ratio, and is suscep-
tible to motion artifacts. Finally, our study does not
explain the mechanisms behind the detected Ab-related
structural and CBF variations. Furthermore, the neuroi-
maging signature of brain amyloidosis estimated by the
PLS regression approach represents the parsimonious set
of neuroimaging variables (i.e., anatomical shape variation
or CBF measures from a subset of brain tissue voxels)
that cumulatively explain the variance in Ab burden max-
imally. These parsimonious set of neuroimaging voxels
identified as good predictors of Ab burden is expected to
be smaller than the set of neuroimaging voxels potentially
with significant Ab-association based on conventional
voxel-based analysis.
In conclusion, MRI is a very attractive candidate for
the identification of inexpensive and noninvasive surro-
gate biomarkers of Ab deposition because it is widely
available, and routinely assessed in clinical practice.
Exploring biomarkers from a range of modalities and/or
disciplines already well established in AD research and
clinical practice may also provide a less invasive, less
expensive, and more practical way to identify individuals
with Ab pathology. Several lines of evidence suggest that
clinical measures, genetic risk factors, and peripheral
blood protein levels can also reflect the likelihood of hav-
ing elevated Ab accumulation and can potentially be
useful for assessing the risk for future conversion into
AD.54–59 Together with the work of others, our findings
could result in development of multidisciplinary and mul-
timodality biomarkers of brain amyloidosis that are reli-
able, minimally invasive, simple to perform, and widely
available. These may include detailed demographic char-
acteristics such as family history, cognitive performance,
and high-throughput biomarker technologies such as
genomics and proteomics. Our approach is expected to
have value for the identification of individuals likely to be
Ab+ in circumstances where cost or logistical problems
prevent Ab detection using CSF analysis or amyloid PET.
This can be used in clinical settings and clinical trials,
aiding subject recruitment and evaluation of treatment
efficacy. Imputation of the Ab-positivity status could also
complement Ab-PET by identifying individuals who
would benefit the most from this assessment.
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